Resalis Therapeutics secured a strategic equity investment from Sanofi to accelerate the development of its lead candidate, RES-010, through a Phase 2 clinical trial.

Oct 28, 2024•about 1 year ago

TurinBiotechnology

Investors

Sanofi

Description

Resalis Therapeutics announced a strategic equity investment from Sanofi to fast-track the development of RES-010, aimed at obesity treatment. This investment validates their approach and supports advancements towards clinical trials offering potential transformative treatments for obesity.

Company Information

Company

Resalis Therapeutics

Location

Turin, Piedmont, Italy

About

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns